LY4515100在健康参与者中的研究
一项针对健康参与者的LY4515100安全性、耐受性和药代动力学特征的1期、随机、研究者和参与者双盲、安慰剂对照、单次和多次递增剂量研究
The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. LY4515100 will be given by itself or with other medicines. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will have 3 parts and will last about 50 days. For each participant in Part A, the study will include a stay in the Clinical Research Unit (CRU) lasting about 6 days. For each participant in Part B, the study will include a stay in the CRU lasting about 15 days. For each participant in Part C, the study will include up to 2 stays in the CRU each lasting between 7-28 days.
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
- 电话号码:1-317-615-4559
- 邮箱:LillyTrials@Lilly.com
研究联系人备份
- 姓名:Physicians interested in becoming principal investigators please contact
- 邮箱:clinical_inquiry_hub@lilly.com
学习地点
-
-
Texas
-
Dallas、Texas、美国、75247
- 招聘中
- Fortrea Clinical Research Unit
-
首席研究员:
- Gene Voskuhl
-
接触:
- 电话号码:866-429-3700
-
-
Wisconsin
-
Madison、Wisconsin、美国、53704
- 尚未招聘
- Fortrea Clinical Research Unit
-
首席研究员:
- Kimberly Cruz
-
接触:
- 电话号码:866-429-3700
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring.
-
Have a body mass index (BMI) within the range of 18.5 to 32.0 kilograms per square meter (kg/m²) (inclusive).
-
Individuals not of childbearing potential (INOCBP) may participate in this trial.
-
Participants in the Combined Oral Contraceptive Arm of Part C only:
- must be 18 to 45 years of age (inclusive).
- have a BMI within the range of 18.5 to 30 kg/m².
- may be healthy pre-menopausal assigned female at birth (AFAB) individuals of child bearing potential (IOCBP).
Exclusion Criteria:
-
Have donated 500 milliliters (mL) of blood within 30 days prior to dosing.
-
Have participated within the last 30 days in a clinical study involving an investigational medicinal product. If the previous investigational product (IP) has a long half-life, 5 half-lives or 30 days (whichever is longer) should have passed.
-
Participants with hemoglobin outside of the local laboratory normal reference range for age and sex, which is judged to be clinically significant by the investigator.
-
Participants with an estimated glomerular filtration rate less than (<) 90 milliliter per minute per 1.73 square meters (mL/min/1.73 m²).
-
Have a 12-lead Electrocardiogram (ECG) abnormality that, in the opinion of the investigator,
-
increases the risks associated with participating in the study
-
may confound ECG data analysis
-
Have used or intend to use over-the-counter or prescription medication including dietary or herbal medications within 7 days, or 14 days if the medication is a potential enzyme inducer, or 5 half-lives (whichever is longer), prior to dosing.
-
Smoke more than 10 cigarettes per day or the equivalent, including electronic cigarettes, and are unable to abide by investigative site smoking restrictions.
-
Have an average weekly alcohol intake that exceeds 14 units per week (males 65 years of age or younger) and 7 units per week (females and males greater than 65 years of age, if applicable)
-
Show evidence of
-
Human immunodeficiency virus (HIV) infection and/or positive human HIV antigen and/or antibodies
-
hepatitis C and/or positive hepatitis C antibody
-
hepatitis B and/or positive hepatitis B surface antigen.
-
Have liver disease.
-
Any clinical condition or procedure (for example, gastrointestinal obstruction, gastric bypass, or cholecystectomy) that may affect the absorption, distribution, or excretion of the study drug and confound pharmacokinetics (PK) assessment.
-
Part C Only:
- Have history of neuropathy of any cause.
- Have impaired hearing or a history of hearing problems.
- Have any medical conditions, medical history, or are taking any medications that are contraindicated in the itraconazole prescribing information, such as prior history of hypersensitivity to itraconazole or other azoles.
- Participants with any known history of thyroid disease
-
Participants in the Combined Oral Contraceptive Arm of Part C only:
- Are current smokers or have used nicotine, including tobacco or nicotine replacement products within 14 days prior to the first dose of combined oral contraceptive (COC), or plan to use nicotine, including tobacco or nicotine replacement products during the study.
- Are at high risk for arterial or venous thrombotic diseases, autoimmune disease with lupus anticoagulants or anti-phospholipid syndrome, major surgery within the past 3 months, anticipated prolonged immobility.
- Have abnormalities indicative of increased risk of VTE on the thrombophilia panel at screening.
- Have undiagnosed abnormal uterine bleeding.
- Have any history of breast, uterine or ovarian cancer.
- Use of Vitamin C (greater than or equal to (≥) 500 mg/day) or acetaminophen within 14 days before dosing.
- Have contraindications for the use of levonorgestrel/ethinyl estradiol.
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:LY4515100 of Part A (SAD)
Single-ascending doses of LY4515100 will be given orally |
given orally |
|
实验性的:LY4515100 of Part B (MAD)
Multiple-ascending doses of LY4515100 will be given orally |
given orally |
|
实验性的:LY4515100 and Itraconazole of Part C
LY4515100 and Itraconazole will be given orally |
given orally given orally |
|
实验性的:LY4515100 and Metformin of Part C
LY4515100 and Metformin will be given orally |
given orally given orally |
|
实验性的:LY4515100 and Transporter Substrates or Renal Marker of Part C
LY4515100 and Transporter Substrates or Renal Marker will be given either orally or intravenously (IV) |
given orally given orally given orally given IV given orally |
|
实验性的:LY4515100 and Midazolam of Part C
LY4515100 will be given orally. Midazolam will be given orally and IV. |
given orally given orally given IV |
|
实验性的:LY4515100 and Combined Oral Contraceptive of Part C
LY4515100, Levonorgestrel, and Ethinyl Estradiol will be given orally |
given orally given orally given orally |
|
安慰剂比较:Placebo Part A
Placebo will be given orally |
given orally |
|
安慰剂比较:Placebo Part B
Placebo will be given orally |
given orally |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of participants with one or more serious adverse event(s) (SAEs) of LY4515100 in Parts A and B
大体时间:Day 1 up to Day 30
|
SAEs of LY4515100 |
Day 1 up to Day 30
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
PK: Geometric Means of Area Under the Concentration-Time Curve From 0 to Infinity [AUC(0-∞)] of LY4515100 in Combination with Itraconazole versus LY4515100 Alone
大体时间:Day 1 through Day 50
|
Day 1 through Day 50
|
|
|
PK: Geometric Means of Cmax of LY4515100 in Combination with Itraconazole versus LY4515100 Alone
大体时间:Day 1 through Day 50
|
Day 1 through Day 50
|
|
|
PK: Geometric Means of AUC(0-∞) of Substrate in Combination with LY4515100 versus Substrate Alone
大体时间:Day 1 through Day 36
|
Day 1 through Day 36
|
|
|
PK: Geometric Means of Cmax of Substrate in Combination with LY4515100 versus Substrate Alone
大体时间:Day 1 through Day 36
|
Day 1 through Day 36
|
|
|
Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of LY4515100
大体时间:Day 1 through Day 11
|
PK: AUC of LY4515100 |
Day 1 through Day 11
|
|
PK: Maximum Observed Drug Concentration (Cmax) of LY4515100
大体时间:Day 1 through Day 11
|
PK: Cmax of LY4515100 |
Day 1 through Day 11
|
|
PK: Time of maximum observed drug concentration (tmax) of LY4515100
大体时间:Day 1 through Day 11
|
PK: tmax of LY4515100 |
Day 1 through Day 11
|
合作者和调查者
调查人员
- 研究主任:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 荷尔蒙
- 激素、激素替代品和激素拮抗剂
- 硫化合物
- 有机化学品
- 杂环化合物,1形
- 杂环化合物
- 杂环化合物,2环
- 杂环化合物,融合环
- Azoles
- 碳氢化合物
- 碳氢化合物,循环
- 碳水化合物
- 羧酸
- 生物碱
- 碳氢化合物,芳香族
- 多环化合物
- 糖苷
- 酰胺
- 丘脑
- 嘌呤
- 嘧啶
- 类固醇
- 融合环化合物
- 苯衍生物
- 碳氢化合物,卤素
- 苯甲酰苯丙胺
- 雌二醇同源物
- 性腺类固醇激素
- 性腺激素
- Biguanides
- 鸟齿
- 胺
- 酸,碳环
- 磺酰胺
- 硫酮
- 苯甲酸盐
- 苯二氮卓
- 三轮唑
- 氟苯烯
- 碳氢化合物,氟
- 哌嗪
- Norpregnenes
- Norpregnanes
- 多骑
- 黄金
- 三二苯甲酸
- 碘苯甲酸盐
- Digitalis糖苷
- 心脏甲苯酚
- 心脏糖苷
- Cardanolides
- Norpregnatrienes
- 雌激素类固醇,烷基化
- 诺曼德尔
- 瑞舒伐他汀钙
- 咪达唑仑
- 地高辛
- 二甲双胍
- 咖啡因
- 伊曲康唑
- 左炔诺孕酮
- 乙炔雌二醇
- Iohexol
其他研究编号
- 27789
- J6V-MC-OIAB (其他标识符:Eli Lilly and Company)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.